Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07610278 | A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia | PHASE2 | NOT YET_RECRUITING | 120 | — | — | Jun 3, 2026 | Jan 28, 2028 | May 27, 2026 | - | — |
Percent (%) change from baseline of PCSK9 levels for QCZ484 + Inclisiran at Month 3
Percent (%) change from baseline of AGT levels for QCZ484 + Inclisiran at Month 3
| Arm | Type | Description |
|---|---|---|
| QCZ484 + Inclisiran | EXPERIMENTAL | QCZ484 + inclisiran, once on Day 1 |
| QCZ484 | ACTIVE_COMPARATOR | QCZ484 + inclisiran placebo, once on Day 1 |
| Inclisiran | ACTIVE_COMPARATOR | Inclisiran + QCZ484 placebo, once on Day 1 |
| Placebo | PLACEBO_COMPARATOR | QCZ484 placebo + inclisiran placebo, once on Day 1 |
| Name | Type | Description |
|---|---|---|
| QCZ484 | DRUG | QCZ484 once on Day 1 |
| Inclisiran | DRUG | Inclisiran once on Day 1 |
| QCZ484 placebo | DRUG | QCZ484 placebo once on Day 1 |
| Inclisiran placebo | DRUG | Inclisiran placebo once on Day 1 |
Inclusion Criteria: * Males or females aged 18 to 75 years. * Diagnosis of primary hypertension. * Treatment with either no, or up to 2 antihypertensive medications at a stable dose for at least 4 weeks preceding screening. * Systolic blood pressure ≥140 and \<165 mmHg based on the mean of 3 sittin...